Propantheline bromide Rx
Generic Name and Formulations:
Propantheline bromide 15mg; tabs.
Roxane Laboratories, Inc.
Indications for Propantheline bromide:
Adjunctive therapy in the treatment of peptic ulcer.
15mg taken 30 minutes before each meal and 30mg at bedtime. Total daily dose: 75mg.
Glaucoma. GI obstruction (eg, pyloroduodenal stenosis, achalasia, paralytic ileus). GU obstruction (eg, bladder-neck obstruction due to prostatic hypertrophy). Intestinal atony of elderly or debilitated. Severe ulcerative colitis. Toxic megacolon. Unstable cardiovascular adjustment in acute hemorrhage. Myasthenia gravis.
High environmental temperature. Monitor for diarrhea; may be symptom of incomplete intestinal obstruction. Heart disease. CHF. Cardiac tachyarrhythmias. Hypertension. Hiatal hernia associated with reflux esophagitis. Autonomic neuropathy. Hepatic or renal disease. Hyperthyroidism. Elderly. Pregnancy (Cat.C). Nursing mothers.
Additive anticholinergic effects with concomitant belladonna alkaloids, narcotic analgesics (eg, meperidine), Class I antiarrhythmics (eg, disopyramide, procainamide, quinidine), antihistamines, phenothiazines (may potentiated sedative effects), tricyclic antidepressants, other anticholinergics. Increased intraocular pressure with concomitant corticosteroids. May potentiate slow-dissolving digoxin tablets; use rapidly-dissolving digoxin tablets instead.
Drying of salivary secretions, decreased sweating, ophthalmic effects (eg, blurred vision, mydriasis, cycloplegia, increased ocular tension), urinary hesitancy and retention, tachycardia, palpitations, loss of sense of taste, headache, nervousness, mental confusion, drowsiness, weakness, dizziness, insomnia, GI upset, constipation, bloating, impotence, lactation suppression, allergic reactions.
Formerly known under the brand name Pro-Banthine.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy